Brokerages expect that ConforMIS Inc (NASDAQ:CFMS) will announce earnings per share (EPS) of ($0.16) for the current quarter, according to Zacks. Three analysts have made estimates for ConforMIS’s earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.14). ConforMIS posted earnings of ($0.27) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 40.7%. The firm is scheduled to issue its next earnings report on Wednesday, February 6th.
According to Zacks, analysts expect that ConforMIS will report full year earnings of ($0.75) per share for the current financial year, with EPS estimates ranging from ($0.85) to ($0.62). For the next year, analysts expect that the company will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.54) to ($0.44). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover ConforMIS.
ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings data on Wednesday, October 31st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.08. ConforMIS had a negative return on equity of 90.97% and a negative net margin of 51.25%. The business had revenue of $28.98 million during the quarter, compared to analysts’ expectations of $19.21 million.
A number of equities research analysts have recently weighed in on the company. Cowen reaffirmed a “buy” rating and issued a $3.00 price objective on shares of ConforMIS in a research note on Friday, November 2nd. Oppenheimer set a $3.00 price objective on ConforMIS and gave the company a “buy” rating in a research note on Thursday, November 1st. Canaccord Genuity dropped their price objective on ConforMIS from $3.00 to $2.50 and set a “buy” rating for the company in a research note on Thursday, November 1st. Finally, Zacks Investment Research cut ConforMIS from a “buy” rating to a “hold” rating in a research note on Wednesday, October 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. ConforMIS presently has an average rating of “Buy” and a consensus target price of $2.45.
Hedge funds and other institutional investors have recently modified their holdings of the company. Macquarie Group Ltd. acquired a new position in ConforMIS during the 2nd quarter worth $131,000. LMR Partners LLP acquired a new position in ConforMIS during the 2nd quarter worth $167,000. Allianz Asset Management GmbH acquired a new position in ConforMIS during the 1st quarter worth $183,000. Spark Investment Management LLC grew its stake in ConforMIS by 60.5% during the 2nd quarter. Spark Investment Management LLC now owns 193,989 shares of the medical instruments supplier’s stock worth $242,000 after purchasing an additional 73,089 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY acquired a new position in ConforMIS during the 2nd quarter worth $296,000. 36.11% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ CFMS opened at $0.54 on Monday. ConforMIS has a twelve month low of $0.42 and a twelve month high of $3.35. The company has a quick ratio of 4.91, a current ratio of 5.71 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $34.21 million, a PE ratio of -0.44 and a beta of 1.16.
ConforMIS Company Profile
ConforMIS, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
See Also: Why is the conference call important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.